牛牛AI助手已提取核心信息
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has successfully addressed a listing deficiency with The Nasdaq Stock Market. The company was previously notified by Nasdaq on September 1, 2023, that it did not meet the minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 required for continued listing on the Nasdaq Global Market. However, ZyVersa Therapeutics received approval on February 29, 2024, to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effectively curing the MVPHS deficiency. The transfer became effective on March 1, 2024, with the company's common stock continuing to trade under the ticker symbol 'ZVSA'. The Nasdaq Capital Market has similar operational characteristics to the Nasdaq Global Market, but with different financial requirements. As of the transfer date, ZyVersa Therapeutics reported having 7,583,863 shares of common stock outstanding.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has successfully addressed a listing deficiency with The Nasdaq Stock Market. The company was previously notified by Nasdaq on September 1, 2023, that it did not meet the minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 required for continued listing on the Nasdaq Global Market. However, ZyVersa Therapeutics received approval on February 29, 2024, to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effectively curing the MVPHS deficiency. The transfer became effective on March 1, 2024, with the company's common stock continuing to trade under the ticker symbol 'ZVSA'. The Nasdaq Capital Market has similar operational characteristics to the Nasdaq Global Market, but with different financial requirements. As of the transfer date, ZyVersa Therapeutics reported having 7,583,863 shares of common stock outstanding.
生物制药公司ZyVersa Therapeutics, Inc. 成功解决了纳斯达克股票市场的上市缺陷。纳斯达克此前曾于2023年9月1日通知该公司，该公司未达到继续在纳斯达克全球市场上市所需的公开持股股票（MVPHS）最低市值500万美元。但是，ZyVersa Therapeutics于2024年2月29日获得批准，将其普通股上市从纳斯达克全球市场转移到纳斯达克资本市场，这有效地弥补了MVPHS的缺陷。此次转让于2024年3月1日生效，该公司的普通股继续以股票代码'ZVSA'进行交易。纳斯达克资本市场的运营特征与纳斯达克全球市场相似，但财务要求不同。截至转让日，ZyVersa Therapeutics报告已发行7,583,863股普通股。
生物制药公司ZyVersa Therapeutics, Inc. 成功解决了纳斯达克股票市场的上市缺陷。纳斯达克此前曾于2023年9月1日通知该公司，该公司未达到继续在纳斯达克全球市场上市所需的公开持股股票（MVPHS）最低市值500万美元。但是，ZyVersa Therapeutics于2024年2月29日获得批准，将其普通股上市从纳斯达克全球市场转移到纳斯达克资本市场，这有效地弥补了MVPHS的缺陷。此次转让于2024年3月1日生效，该公司的普通股继续以股票代码'ZVSA'进行交易。纳斯达克资本市场的运营特征与纳斯达克全球市场相似，但财务要求不同。截至转让日，ZyVersa Therapeutics报告已发行7,583,863股普通股。
有用
没用